Update in Immunotherapy for Advanced Non-small Cell Lung Cancer: Treatment Sequencing and Best Choices

• Type: Other Publications
• Date: 2023

Authors

Roque, K (Author) Other; Ruiz, R (Author) Other; Mas, L (Author) Other; Daniel Pozza (Author) FMUP; Vancini, M (Author) Other; Silva, JA (Author) Other; De Mello, RA (Author) Other

Other information

Authenticus ID: P-00Z-GV7

DOI: 10.20944/preprints202307.1242.v1

Abstract (EN): <jats:p>The advent of immunotherapy has revolutionized the treatment of advanced non-small cell lung cancer (NSCLC), improving the prognosis of this disease and becoming a key part of the treatment, especially in the population without an oncogenic driver mutation. Two different groups of immune checkpoint inhibitors (ICIs) are used in lung cancer: Anti- Cytotoxic T-lymphocyte antigen-4 (Anti-CTLA 4) and Anti- T-cell receptor programmed cell death-1 or its ligand (Anti-PD-1 and Anti PD-L1). Here in, we review an uptodate on the use of immunotherapy for advanced NSCLC.</jats:p>

Language: English

Type (Professor's evaluation): Scientific